CN113797310A - Pet joint health-care preparation and preparation method and application thereof - Google Patents
Pet joint health-care preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN113797310A CN113797310A CN202010539789.3A CN202010539789A CN113797310A CN 113797310 A CN113797310 A CN 113797310A CN 202010539789 A CN202010539789 A CN 202010539789A CN 113797310 A CN113797310 A CN 113797310A
- Authority
- CN
- China
- Prior art keywords
- powder
- joint
- preparation
- weight
- pet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000000843 powder Substances 0.000 claims abstract description 56
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 23
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960002442 glucosamine Drugs 0.000 claims abstract description 22
- 230000037231 joint health Effects 0.000 claims abstract description 20
- 239000012528 membrane Substances 0.000 claims abstract description 20
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 19
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 19
- 235000013601 eggs Nutrition 0.000 claims abstract description 19
- 239000000796 flavoring agent Substances 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 235000019634 flavors Nutrition 0.000 claims abstract description 16
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 14
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 13
- 239000011707 mineral Substances 0.000 claims abstract description 13
- 150000007524 organic acids Chemical class 0.000 claims abstract description 13
- 229920002261 Corn starch Polymers 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 11
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 11
- 239000008120 corn starch Substances 0.000 claims abstract description 11
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 11
- 239000008103 glucose Substances 0.000 claims abstract description 11
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 11
- 235000013336 milk Nutrition 0.000 claims abstract description 11
- 239000008267 milk Substances 0.000 claims abstract description 11
- 210000004080 milk Anatomy 0.000 claims abstract description 11
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract description 4
- 230000000996 additive effect Effects 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 22
- 238000011049 filling Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 239000002417 nutraceutical Substances 0.000 claims description 14
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 235000010755 mineral Nutrition 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- 241000287828 Gallus gallus Species 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000005667 attractant Substances 0.000 claims description 6
- 230000031902 chemoattractant activity Effects 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001527 calcium lactate Substances 0.000 claims description 4
- 229960002401 calcium lactate Drugs 0.000 claims description 4
- 235000011086 calcium lactate Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 230000008961 swelling Effects 0.000 abstract description 9
- 210000000845 cartilage Anatomy 0.000 abstract description 7
- 210000001179 synovial fluid Anatomy 0.000 abstract description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 39
- 210000001503 joint Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000000629 knee joint Anatomy 0.000 description 5
- 210000002414 leg Anatomy 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 4
- 230000001050 lubricating effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 239000004227 calcium gluconate Substances 0.000 description 3
- 229960004494 calcium gluconate Drugs 0.000 description 3
- 235000013927 calcium gluconate Nutrition 0.000 description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 208000030175 lameness Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- KXLUWEYBZBGJRZ-POEOZHCLSA-N Canin Chemical compound O([C@H]12)[C@]1([C@](CC[C@H]1C(=C)C(=O)O[C@@H]11)(C)O)[C@@H]1[C@@]1(C)[C@@H]2O1 KXLUWEYBZBGJRZ-POEOZHCLSA-N 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- GPFVKTQSZOQXLY-UHFFFAOYSA-N Chrysartemin A Natural products CC1(O)C2OC2C34OC3(C)CC5C(CC14)OC(=O)C5=C GPFVKTQSZOQXLY-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 206010073767 Developmental hip dysplasia Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010050256 Dysstasia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000007446 Hip Dislocation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000001726 jatropha manihot extract Substances 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940106668 yucca extract Drugs 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/26—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/25—Shaping or working-up of animal feeding-stuffs by extrusion
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
The invention provides a pet joint health-care preparation which is characterized by comprising the following components: (1) a mineral; (2) an organic acid; (3) a flavor phagostimulant; (4) a carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) a functional ingredient selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate and glucosamine. The invention also provides a preparation method of the health-care preparation and application of the health-care preparation as an additive for pet joint health care. The joint health care preparation can be used for daily joint health care of pets, increases the joint synovial fluid amount, strengthens cartilage, enables inflamed or injured joints to rapidly subside swelling, and recovers the normal state, thereby opening a new thought for joint health care of pets.
Description
Technical Field
The invention relates to the technical field of pet health care, in particular to a pet joint health care preparation and a preparation method and application thereof
Background
During the pet growth process, joint problems cannot be ignored. However, the calcium supplement of many pet owners is equivalent to joint health care, which is true. The discomfort of the joints can cause the pet such as dog to move inconveniently and lose the activity of the pet in the past day.
The joints can not be opened when the pet acts at one time, so the quality of the joints affects the life of the pet. Hip joint dysplasia, bone degeneration, osteoporosis, various arthritis and the like are the most common joint problems for pets. However, the main causes of these disorders are:
excessive obesity leads to lack of exercise: the pet may be too fat due to pet species, eating habits, lack of exercise, sterilization operation, age and other factors, and the excessive obesity of the pet may increase the burden of various tissues and organs of the body, such as joints, so that the probability of causing bone problems and arthritis is higher, and the postoperative recovery is more difficult.
Overwork due to excessive exercise: the normal articular cartilage is used as a 'shock absorber' of the joint, the joint can play a role in buffering and lubricating when moving, if a pet moves for a long time and excessively, the joint cartilage can be quickly worn, and the joint diseases are easily caused by the excessive wear of the joint cartilage.
Aging of bone due to aging: the physical function of the pet gradually entering the elderly is gradually degraded, and the joint is usually gradually aged and stiffened.
Inheritance in nature: congenital factors are mainly genetic defects, e.g., hip dysplasia, which is one of the most common joint diseases in dogs. The incidence of the severe pets is high, so that the pets suffering from the disease should be strictly prohibited from breeding in the breeding process.
Difficulty in recovery after joint surgery: pets are not easy to completely restrict movement after joint surgery, so that some movement is often accompanied after surgery, resulting in slow joint recovery after surgery.
Cn201510733742.x discloses a pet joint health agent and a preparation method thereof, the pet joint health agent comprises the following components: chondroitin sulfate, glucosamine hydrochloride, dimethyl sulfone, collagen, vitamin D3, vitamin E, zinc gluconate, manganese gluconate, calcium gluconate, yucca extract, flavoring agent, and adjuvants; the flavoring agent is chicken liver powder or beef powder. The auxiliary materials are starch and lactose, and the weight ratio is starch: lactose was 4: 1. The joint health care agent for pets adopts glucosamine, which is considered as an important precursor of biosynthetic cartilage tissues, and the lack of the glucosamine in vivo can directly cause various osteoarticular diseases; the health-care agent also adopts glucosamina, which is considered as a natural substance extracted from marine organism carapace, and can become the most effective medicine without side effect after being taken by combining chondroitin as a nutritional agent; the drug which is the combination of glucosamine and chondroitin only can play a role in relieving inflammation. On the contrary, the health care agent disclosed in the patent application is supplemented with trace elements, vitamins, collagen, plant extracts and other nutrients required for healthy growth of animal bones besides relieving inflammation, so that the rapid recovery of the animal bones is promoted, and meanwhile, flavoring agents (chicken liver powder and beef powder) are added, so that the palatability of the product is improved.
The invention provides a completely different formula aiming at the health care problem of pet joints, and opens a completely different new idea for the health care of pet joints.
Disclosure of Invention
In order to solve the health care problem of pet joints, the invention provides a pet joint health care preparation, which comprises the following components: (1) a mineral; (2) an organic acid; (3) a flavor phagostimulant; (4) a carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) a functional ingredient selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
In a second aspect, the present invention provides a method of preparing a nutraceutical formulation according to the first aspect of the present application, said method comprising the steps of:
(1) mixing materials: sieving and mixing mineral substances, organic acid, flavor attractant, carrier and chondroitin sulfate and glucosamine which can be selected as functional components, adding water and mixing to obtain paste;
(2) drying: drying and cooling the paste to room temperature;
(3) addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agents which can be selected as functional components, uniformly mixing and sieving to obtain a mixed material;
(4) tabletting: and taking out the mixed material, and tabletting by using a tabletting machine to obtain the health-care preparation.
In a third aspect, the present invention provides the use of a hygiene preparation according to the first aspect of the invention as an additive for the hygiene of joints in pets.
The invention provides a brand-new pet joint health care preparation, which contains functional components such as chondroitin sulfate, glucosamine, egg membrane polypeptide powder and the like, can be used for daily joint health care of pets, increases the joint lubricating fluid quantity, strengthens cartilage, enables inflamed or damaged joints to quickly reduce swelling, recovers the normal state, and opens a new thought for joint health care of pets.
Drawings
Fig. 1 shows the joint state of a dog fed with a health formulation according to one embodiment of the present invention only in the first week (a), the second week (B) and the third week (C). The left and right images show photographs of the joint taken at different angles, respectively.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
The invention provides a pet joint health care preparation, which comprises the following components: (1) a mineral; (2) an organic acid; (3) a flavor phagostimulant; (4) a carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) a functional ingredient selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
In the formulation of the present invention, chondroitin sulfate is an enzyme that can absorb moisture into chondroitin sulfate proteoglycan molecules to thicken cartilage and increase synovial fluid volume in joints, and inhibit enzymes such as collagenase, elastase, cathepsin, and the like that destroy cartilage. Glucosamine, which is an important raw material for forming a lubricating substance between articular cartilage tissues and joints, can provide functions of joint lubrication and glucosamine protection, stimulate chondrocytes to generate more collagen, glycoprotein and glycosaminoglycan, allow joints to absorb more lubricating liquid, and ensure the softness of the joints. The egg membrane polypeptide is extracted from a fibrous membrane located between the egg membrane, i.e., the eggshell and the egg white, and clinging to the papillary layer of the eggshell. The inventor finds that the health-care preparation containing the functional components such as chondroitin sulfate, glucosamine, egg membrane polypeptide and the like in the formula system has a remarkable effect on joint health care.
In some preferred embodiments, the nutraceutical formulation consists of: (1) a mineral; (2) an organic acid; (3) a flavor phagostimulant; (4) a carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) a functional ingredient selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate and glucosamine. In other preferred embodiments, the carrier consists of glucose, maltodextrin, corn starch, milk powder and egg yolk powder. In other preferred embodiments, the functional component consists of egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
In some preferred embodiments, the mineral is 1.5 to 5 parts by weight (e.g., 2, 3, or 4 parts by weight); the organic acid is 0.02 to 0.5 parts by weight (e.g., 0.05, 0.1, 0.2, 0.3, or 0.4 parts by weight); the flavor phagostimulant is 7 to 17 parts by weight (e.g., 10 or 15 parts by weight); the carrier is 27 to 88 parts by weight (e.g., 30, 40, 50, 60, 70, or 80 parts by weight); the functional component is from 4.51 to 23 parts by weight (e.g., 5, 10, 15, or 20 parts by weight).
In some preferred embodiments, the mineral is calcium lactate; the organic acid is lactic acid; and/or the flavor phagostimulant is selected from the group consisting of beer yeast powder and chicken liver powder.
In other preferred embodiments, the flavor phagostimulant comprises beer yeast powder and chicken liver powder; the carrier comprises glucose, maltodextrin, corn starch, milk powder and yolk powder; and/or the functional component comprises egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
In some preferred embodiments, the flavor phagostimulant consists of beer yeast powder and chicken liver powder. More preferably, the carrier is composed of glucose, maltodextrin, corn starch, milk powder and egg yolk powder. Even more preferably, the functional component consists of egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
In other preferred embodiments, the nutraceutical formulation comprises:
in other preferred embodiments, the nutraceutical formulation is a tablet and further comprises a tableting aid selected from the group consisting of microcrystalline cellulose and magnesium stearate; preferably, the tableting aid is 0.5 to 4.6 parts by weight (e.g. 1, 2, 3 or 4 parts by weight).
In other preferred embodiments, the microcrystalline cellulose is 0.3 to 3.5 parts by weight (e.g., 1.0, 2, or 3 parts by weight) and the magnesium stearate is 0.2 to 1.1 parts by weight (e.g., 0.5 or 1.0 parts by weight).
The health care preparation is suitable for all-stage dogs and cats. Can be fed twice daily. Directly eating or grinding, and adding into food for feeding.
The amounts given are, for example, 1g per tablet and can be determined as follows.
In a second aspect, the present invention provides a method of preparing a nutraceutical formulation according to the first aspect of the present application, said method comprising the steps of:
(1) mixing materials: sieving and mixing mineral substances, organic acid, flavor attractant, carrier and chondroitin sulfate and glucosamine which can be selected as functional components, adding water and mixing to obtain paste;
(2) drying: drying and cooling the paste to room temperature;
(3) addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agents which can be selected as functional components, uniformly mixing and sieving to obtain a mixed material;
(4) tabletting: and taking out the mixed material, and tabletting by using a tabletting machine to obtain the health-care preparation.
In some preferred embodiments, the method further comprises: (5) and (3) sterilizing and filling: sterilizing and filling the health preparation before filling, and then sterilizing after filling.
In some more specific embodiments, the method comprises the steps of:
(1) mixing materials: sieving mineral matter, organic acid, flavor attractant, carrier and chondroitin sulfate and glucosamine which can be selected as functional components with a 100-mesh sieve to prevent caking materials and impurities from being mixed, uniformly mixing the materials after sieving, and adding a proper amount of water to fully mix into paste;
(2) drying: putting the paste into a drying oven for drying at the drying temperature of 70 ℃ for 6 hours, and cooling the dried material to room temperature;
(3) addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agents which can be selected as functional components into the cooled material, fully and uniformly mixing, and sieving the uniformly mixed material with a 18-mesh sieve for grading to obtain a mixed material;
(4) tabletting: taking out the mixed material, and tabletting with a single-punch tablet press at a humidity of less than or equal to 50%, a temperature of less than or equal to 28 ℃ and a pressure of 3.00-5.00 kg/cm2Tabletting to obtain the tablet.
(5) And (3) sterilization: sterilizing the tablets prior to filling;
(6) filling: transferring the sterilized tablets to a filling line, and respectively filling and sealing the tablets under the condition of starting a 2000-air-volume dynamic air sterilizer for 60 minutes (to avoid secondary pollution);
(7) and (3) sterilizing after filling: and (4) after filling, sterilizing by adopting a pasteurization method (at 70-80 ℃ for 30-40 minutes).
In a third aspect, the present invention provides the use of a hygiene preparation according to the first aspect of the invention as an additive for the hygiene of joints in pets. Preferably, the pet is a pet dog or a pet cat.
Examples
The present invention will be further illustrated by the following examples, but the scope of the invention as claimed is not limited to these examples. The starting materials used in the examples are, unless otherwise indicated, conventional starting materials which are commercially available.
Preparation example
Pet joint care preparations were prepared according to the formula shown in table I in the following manner (if no component was present, the use of the corresponding component was dispensed with):
1. mixing materials: sieving calcium lactate, lactic acid or calcium gluconate, beer yeast powder, chicken liver powder, glucose, maltodextrin, milk powder, yolk powder, chondroitin sulfate (Wuhan Yimei Biotech Co., Ltd.), glucosamine (Wuhan Yimei Biotech Co., Ltd.) and corn starch with 100 mesh sieve to prevent agglomeration and impurities from mixing, sieving, mixing, and adding appropriate amount of water for mixing.
2. Drying: and (3) putting the uniformly mixed materials into an oven for drying at the drying temperature of 70 ℃ for 6 hours, and cooling the dried materials to room temperature.
3. Adding other components: adding formula amount of bovine collagen (Wuhan Shengshiyuan biological technology, Inc.), egg membrane polypeptide powder (Hubei Shen Yifeng biological technology, Inc.), microcrystalline cellulose and magnesium stearate into the cooled material, mixing, and sieving with 18 mesh sieve.
4. Tabletting: taking out the mixed material, and tabletting with a single-punch tablet press at a humidity of 50% or less, a temperature of 28 deg.C or less and a pressure of 4.00kg/cm2Tabletting to obtain the finished product of the joint sheet for pets (0.7 g/sheet).
5. And (3) sterilization: sterilizing before filling the tablets.
6. Filling: and transferring the sterilized tablets to a filling line, and respectively filling and sealing the tablets with the two specifications under the condition of starting a 2000-air-volume dynamic air sterilizer for 60 minutes (to avoid secondary pollution).
7. And (3) sterilizing after filling: after filling, pasteurization was carried out (75 ℃, 35 minutes).
TABLE I formulation (parts by weight) used in the respective preparation examples
| Components | Formulation 1 | Formulation 2 | Formulation 3 | Formulation 4 |
| Calcium lactate | 0 | 0 | 2 | 2 |
| Milk powder | 10 | 10 | 10 | 10 |
| Glucose | 6 | 9 | 6 | 6 |
| Chicken liver powder | 9 | 9 | 9 | 9 |
| Egg yolk powder | 3 | 3 | 3 | 3 |
| Beer yeast powder | 5 | 5 | 5 | 5 |
| Chondroitin sulfate | 2.3 | 2.3 | 2.3 | 2.3 |
| Glucosamine | 15 | 0 | 15 | 15 |
| Maltodextrin | 38.68 | 45.18 | 38.68 | 40.18 |
| Microcrystalline cellulose | 3 | 3 | 3 | 3 |
| Magnesium stearate | 0.5 | 0.5 | 0.5 | 0.5 |
| Corn starch | 3 | 10 | 3 | 3 |
| Egg membrane polypeptide powder | 1 | 1 | 1 | 1 |
| Lactic acid | 0.02 | 0.02 | 0.02 | 0.02 |
| Bovine collagen | 1.5 | 0 | 1.5 | 0 |
| Calcium gluconate | 2 | 2 | 0 | 0 |
Pet joint health preparations (sometimes referred to as "joint sheets of the present invention") were prepared according to formulas 1 to 4 in preparation examples 1 to 4, respectively.
Test example 1: test of joint health Effect
Animals used in the experimental examples: shanxi Lanling test dog house arthritis model beagle dog above 2 years old.
The building method of the arthritis dog model comprises the following steps: the egg protein solution (20mg/ml), the BCG and the Freund's incomplete adjuvant (the proportion of the three is lml: 2 ml: lm1) are mixed under a homogenizer at 1500r/min to prepare a mixed emulsion. The dogs were then injected intraluminally with 5mg egg protein in the unilateral knee joint. Pathological observation shows that the diameter and the surface temperature of the joint greatly rise on the 1 st day after egg protein injection, and the injected hindlimb appears crippled within one week.
Joint symptoms: the symptoms of stiff movement, no active movement, reduced movement, local arthrocele, repeated licking of the arthrocele part, difficult pain of dogs after touching, difficulty in standing and walking, and difficulty in moving or lameness.
The treatment scheme comprises the following steps: feeding basic full-value dog food (ROYAL CANIN Royal dog food) and the joint health preparation prepared in the preparation examples 1-4, 3 tablets each time, 2 times a day, and feeding period of 24 days. The joint site recovery was observed and the degree of swelling recorded, with the results shown in table 1 and fig. 1.
TABLE 1 results of joint recovery status
| Joint item | Swelling degree of the joints in week 1 (mm) | Swelling degree of 2 nd week joint (mm) | Swelling degree of the 3 rd week joint (mm) |
| Preparation example 1 | 141-122＝19 | 137-122＝15 | 134-122＝12 |
| Preparation example 2 | 138-120＝18 | 134-120＝14 | 133-120＝13 |
| Preparation example 3 | 141-117＝24 | 137-117＝20 | 132-117＝15 |
| Preparation example 4 | 139-119＝20 | 131-119＝12 | 124.5-119＝5.4 |
The data in the table above are expressed as the diseased joint circumference at the predetermined time point-initial joint circumference before injection-degree of swelling.
The treatment effect is as follows: the therapeutic effect is shown in table 1. When the health care preparations of the preparation examples 1 to 4 are fed, the knee joint part of the dog on the unilateral side of the left leg is obviously swollen, the dog limps and feels painful, and the activity is reduced in the first week. In the second week, the swelling of the unilateral knee joint of the left leg is slightly relieved, and the joint circumference is reduced and slight lameness occurs. At the third week, the left leg unilateral knee joint of the dogs fed the health care formulations of preparation examples 1 to 3 remained swollen, the joint circumference slightly decreased, and slight lameness remained; the swelling of the knee joint on one side of the left leg of the dog fed with the health care preparation of the preparation example 4 is obviously relieved, the circumferences of the bilateral joints are basically recovered to be close to consistent, the forces of the joints of the two legs are uniform, and the activity is increased (see figure 1).
Test example 2: food calling test
Test animals: 14 beagle dogs aged 2 years or older (7 male dogs, 7 female dogs. initial body weight was around 10 kg, and the inter-individual variation was within 1 kg).
The test contents are as follows: the total of 3 times is 8 am. The test group or the control group had 3 pieces of each of the articular pieces, and 6 pieces of the articular pieces were randomly placed. Every two plates are placed in the same parallel area with a distance of 15 cm. Each time 1 dog was led to an independent experimental area, pet dogs were allowed to freely move to feed, and 14 dogs were individually selected. The number of selections of 2 articular pieces was recorded. The results are shown in Table 2.
Table 2 taste test selection results for the articular tablets of the examples and the comparative articular tablets
| For the first time | For the second time | The third time | Total number of selections | Ratio of occupation of | |
| The number of times of selecting the joint sheet of the invention | 9 | 10 | 11 | 30 | 71.4％ |
| Comparing the number of times of selecting the joint sheet | 5 | 4 | 3 | 12 | 28.6％ |
And (4) conclusion: the taste experiment of the joint sheet for pets shows that the joint sheet for pets prepared by the method provided by the invention is higher in each selection test and the final total selection times compared with the comparative joint sheet, and shows that the joint sheet provided by the invention has better food calling performance, can promote the diet of pets and further provides a basis for the nutrition absorption of animals.
Test example 3: clinical comprehensive effect test
Experimental animals: 14 beagle dogs with similar physiological status over 2 years old (half of the male and female, initial weight individual difference within 1 kg)
Grouping experiments: according to the principle that the body weights are similar and the male half and the female half are respectively determined, the test group is divided into 2 groups, 8 test groups and 4 control groups.
Wherein the test group is fed with basic full-price dog food and the joint tablet (3 tablets each time, 2 times per day), and the control group is fed with basic full-price dog food and a commercially available control joint tablet (4 tablets each time, 2 times per day), and the feeding period is 30 days.
Feeding and managing test dogs: 14 beagle dogs were raised in a single cage. The body weight was weighed on days 0, 7, 14, 21, 30 at the start of the test. The night soil is regularly cleaned, the dog house is cleaned, the water basin is cleaned and the clean drinking water is replaced every morning. Recording the state of the excrement during the excrement cleaning. The test group is directly fed with 3 joint tablets of the invention per dog at 8 am every day, the control group is fed with 4 commercially available control joint tablets (MAG pet product Jingdong self-service flagship shop) every day, and the control group is fed with 150g of basic full-price dog food per dog at 9 am every day. The water is freely drunk all day. A test group is fed at 16 pm with 3 pieces of the joint sheet of the invention per dog and a control group with 4 pieces of the commercially available control joint sheet, and after half an hour, the test group is fed with 200g of basic full-price dog food per dog, and the dog is tied outside a dog house at regular time every day for proper exercise.
The joint sheet feeding mode: taking the joint sheet in a clean empty feed basin, and directly feeding the joint sheet in 8 am: 00 and 16 pm: 00 is carried out. If direct feeding is feasible, the method is used in the whole test process. If the individual dog does not eat the feed by adopting a direct feeding mode, the joint sheet is crushed and directly mixed into basic ration for feeding, and the feed is still fed for 2 times.
Detection indexes are as follows: recording the weight, observing the ingestion condition, the defecation condition, the hair state and the activity every day, recording in detail, and carrying out mathematical statistics analysis on the experimental result after the experiment is finished.
And (3) test results: the results are shown in Table 3.
TABLE 3 comparison of the results of the comprehensive results
And (4) conclusion: as can be seen from the table, the weight of the dogs in the test group and the dogs in the control group do not change greatly overall, and compared with the commercially available control joint sheet, the joint sheet disclosed by the invention can be used for more effectively promoting the weight increase of the test dogs in the later feeding period. The defecation state shows that the joint piece of the invention is more harmless to intestines and stomach compared with the commercially available control joint piece. The results of food intake, hair state, mental state and the like show that the joint sheet of the invention and the commercially available control joint sheet do not have adverse effects on the food intake, the hair state and the mental state on the whole, and the effects of the two are not obviously different.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
1. A pet joint health preparation is characterized by comprising the following components:
(1) a mineral; (2) an organic acid; (3) a flavor phagostimulant; (4) a carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) a functional ingredient selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
2. A nutraceutical formulation according to claim 1, characterized in that:
1.5 to 5 parts by weight of mineral;
the organic acid is 0.02 to 0.5 part by weight;
the flavor attractant is 7 to 17 parts by weight;
the carrier is 27 to 88 parts by weight;
the functional component is 4.51 to 23 parts by weight.
3. A nutraceutical formulation according to claim 1, characterized in that:
the mineral is calcium lactate;
the organic acid is lactic acid; and/or
The flavor phagostimulant is selected from the group consisting of beer yeast powder and chicken liver powder.
4. A nutraceutical formulation according to any of claims 1 to 3, characterized in that:
the flavor attractant comprises beer yeast powder and chicken liver powder;
the carrier comprises glucose, maltodextrin, corn starch, milk powder and yolk powder; and/or
The functional components comprise egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
5. The nutraceutical formulation according to any one of claims 1 to 4, comprising:
6. the nutraceutical formulation according to any one of claims 1 to 5, wherein the nutraceutical formulation is a tablet and further comprises a tableting aid selected from the group consisting of microcrystalline cellulose and magnesium stearate; preferably, the tableting aid is 0.5 to 4.6 parts by weight.
7. The nutraceutical formulation of claim 6, wherein the microcrystalline cellulose is present at 0.3 to 3.5 parts by weight and the magnesium stearate is present at 0.2 to 1.1 parts by weight.
8. A process for the preparation of a nutraceutical formulation according to any of claims 1 to 7, comprising the steps of:
(1) mixing materials: sieving and mixing mineral substances, organic acid, flavor attractant, carrier and chondroitin sulfate and glucosamine which can be selected as functional components, adding water and mixing to obtain paste;
(2) drying: drying and cooling the paste to room temperature;
(3) addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agents which can be selected as functional components, uniformly mixing and sieving to obtain a mixed material;
(4) tabletting: and taking out the mixed material, and tabletting by using a tabletting machine to obtain the health-care preparation.
9. The method of claim 8, further comprising: (5) and (3) sterilizing and filling: sterilizing and filling the health preparation before filling, and then sterilizing after filling.
10. Use of a nutraceutical formulation according to any of claims 1 to 7 as an additive for joint health in pets; preferably, the pet is a pet dog or a pet cat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010539789.3A CN113797310B (en) | 2020-06-15 | 2020-06-15 | Pet joint health care preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010539789.3A CN113797310B (en) | 2020-06-15 | 2020-06-15 | Pet joint health care preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113797310A true CN113797310A (en) | 2021-12-17 |
| CN113797310B CN113797310B (en) | 2024-04-12 |
Family
ID=78892232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010539789.3A Active CN113797310B (en) | 2020-06-15 | 2020-06-15 | Pet joint health care preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113797310B (en) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916565A (en) * | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| WO2000056164A1 (en) * | 1999-03-22 | 2000-09-28 | Kal Kan Foods, Inc. | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| WO2001032188A1 (en) * | 1999-11-02 | 2001-05-10 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
| US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
| AU2005200953A1 (en) * | 1999-03-22 | 2005-03-24 | Mars, Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same |
| US20080069862A1 (en) * | 2006-09-15 | 2008-03-20 | Marni Markell Hurwitz | Joint preserving nutritional vitamin, mineral and herbal pet supplement |
| CN101322551A (en) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | Combination for increasing bone density and repairing articular cartilage |
| CN103143002A (en) * | 2013-03-29 | 2013-06-12 | 武汉中博绿亚生物科技有限公司 | Healthcare agent for pet bone joint and preparation method of healthcare agent |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| CN108323764A (en) * | 2018-01-19 | 2018-07-27 | 湖北神地生物科技有限公司 | A method of extraction membranes of fowl eggshells polypeptide simultaneously prepares Bones and joints health products |
| CN108450652A (en) * | 2018-02-07 | 2018-08-28 | 上海宠幸宠物用品有限公司 | A kind of health food and preparation method thereof for repairing pet dog joint injury |
| CN109984269A (en) * | 2017-12-29 | 2019-07-09 | 瑞普（天津）生物药业有限公司 | It is a kind of with the pet nutrition cream and preparation method of replenishing the calcium and keep articulation health |
| CN110859247A (en) * | 2019-11-11 | 2020-03-06 | 深圳市红瑞生物科技有限公司 | Composition, preparation method and application thereof in preparation of medicines, health-care products and foods for treating joint diseases of pets |
-
2020
- 2020-06-15 CN CN202010539789.3A patent/CN113797310B/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916565A (en) * | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| WO2000056164A1 (en) * | 1999-03-22 | 2000-09-28 | Kal Kan Foods, Inc. | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| AU2005200953A1 (en) * | 1999-03-22 | 2005-03-24 | Mars, Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same |
| WO2001032188A1 (en) * | 1999-11-02 | 2001-05-10 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
| US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
| US20080069862A1 (en) * | 2006-09-15 | 2008-03-20 | Marni Markell Hurwitz | Joint preserving nutritional vitamin, mineral and herbal pet supplement |
| CN101322551A (en) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | Combination for increasing bone density and repairing articular cartilage |
| CN103143002A (en) * | 2013-03-29 | 2013-06-12 | 武汉中博绿亚生物科技有限公司 | Healthcare agent for pet bone joint and preparation method of healthcare agent |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| CN109984269A (en) * | 2017-12-29 | 2019-07-09 | 瑞普（天津）生物药业有限公司 | It is a kind of with the pet nutrition cream and preparation method of replenishing the calcium and keep articulation health |
| CN108323764A (en) * | 2018-01-19 | 2018-07-27 | 湖北神地生物科技有限公司 | A method of extraction membranes of fowl eggshells polypeptide simultaneously prepares Bones and joints health products |
| CN108450652A (en) * | 2018-02-07 | 2018-08-28 | 上海宠幸宠物用品有限公司 | A kind of health food and preparation method thereof for repairing pet dog joint injury |
| CN110859247A (en) * | 2019-11-11 | 2020-03-06 | 深圳市红瑞生物科技有限公司 | Composition, preparation method and application thereof in preparation of medicines, health-care products and foods for treating joint diseases of pets |
Non-Patent Citations (3)
| Title |
|---|
| ROBERT M. LAUDER: "Chondroitin sulphate: A complex molecule with potential impacts on a wide range of biological systems", 《COMPLEMENTARY THERAPIES IN MEDICINE》 * |
| 刘晓琳;邹连生;刘卫;: "浅谈关节保护剂在犬骨关节炎上应用", 养犬 * |
| 李宇: "补肾壮筋汤联合盐酸氨基葡萄糖对大鼠膝软骨细胞 增殖及凋亡影响的研究", 《中国骨质疏松杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113797310B (en) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7485325B2 (en) | Animal food supplement compositions and methods of use | |
| US5071878A (en) | Use of methylsulfonylmethane to enhance diet of an animal | |
| US4616039A (en) | Methylsulfonylmethane in dietary products | |
| US4863748A (en) | Dietary products and uses comprising methylsulfonylmethane | |
| Souza et al. | Lactation performance and diet digestibility of dairy cows in response to the supplementation of Bacillus subtilis spores | |
| CN105901305A (en) | Antibiotic substitute feed additive, its formula, feed with antibiotic substitute feed additive and production method of feed with antibiotic substitute feed additive | |
| US4973605A (en) | Use of methylsulfonylmethane to relieve pain and relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals | |
| US4914135A (en) | Use of Methylsulfonylmethane to treat parasitic infections | |
| Varga | Rabbit basic science | |
| EP0481396A2 (en) | Tannin extract of sweet chestnut wood, a process for the preparation thereof and its use | |
| Johnson-Delaney | Ferret nutrition | |
| CN106719421A (en) | A kind of diseases prevention cultural method of rabbit | |
| JP2009523453A (en) | Morinda citrifolia (Yaeyama Aoki) fortified product for administration to animals | |
| CN113797310B (en) | Pet joint health care preparation and preparation method and application thereof | |
| CN101370391A (en) | Morinda citrifolia enhanced products for administration to animal | |
| AU2003204441A1 (en) | Animal Food Supplement Compositions and Methods of Use | |
| CN113796456A (en) | Pet joint nutritional preparation and preparation method and application thereof | |
| Böhm et al. | The impact of feeding a high-fibre and high-fat concentrated diet on the recovery of horses suffering from gastric ulcers. | |
| CN113796465B (en) | Nutritional powder for dogs as well as preparation method and application thereof | |
| Smith | Textbook of Rabbit Medicine-E-Book: Textbook of Rabbit Medicine-E-Book | |
| Biswal et al. | Prevalence and therapeutic management of indigestion in milch cows in and around Bhubaneswar of Odisha, India | |
| Smith | Textbook of Rabbit Medicine | |
| Afolabi et al. | Growth Performance, Nutrient Digestibility and Economy of Rabbits Fed Varying Dietary Levels of Cameroon Pepper Fruit Meal | |
| CN115886145A (en) | Hair removal ball tablet for cats and preparation method thereof | |
| RU2663014C1 (en) | Method of manufacturing a biologically active feed additive for animals and birds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |